Results 201 to 210 of about 57,090 (240)

Bridging FDA Adverse Event Reporting System (FAERS) and Clinical Practice: Comprehensive Characterization of Immune Checkpoint Inhibitors Toxicities in Geriatric Lung Cancer Patients

Thoracic Cancer, Volume 17, Issue 6, March 2026.
Elderly lung cancer patients face increased risks of severe and fatal AEs during ICIs treatment. Reports concerning males, Asians, and anti‐PD‐1 recipients were associated with higher odds of a fatal outcome. Immune‐mediated pneumonitis is the most frequently reported severe AE, calling for heightened vigilance for these high‐risk subgroups.
Yumeng Tian, Xin Nie, Yue Yuan, Qian Wei, SiQi Zhang, Lin Li   +5 more
wiley   +1 more source

Large Language Models in Cardiovascular Imaging: Current Applications and Future Prospects

Med Research, Volume 2, Issue 1, Page 22-25, March 2026.
Weifeng Yuan, Rong Xu, Shengkun Peng, Yingkun Guo   +3 more
wiley   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1271-1287, March 2026.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Cardiotropic Gene Therapy for Heart Failure: Translational Lessons From AB‐1002

MedComm – Future Medicine, Volume 5, Issue 1, March 2026.
Nghia Phu Nguyen, Phillip Tran
wiley   +1 more source

IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer

Cancer Science, Volume 117, Issue 3, Page 749-758, March 2026.
The global Phase 3 IMpower010 study (NCT02486718) evaluated atezolizumab versus best supportive care (BSC) after complete resection and adjuvant platinum‐based chemotherapy in patients with stage IB–IIIA non‐small cell lung cancer (NSCLC). Here, we report updated efficacy and safety results from the disease‐free survival (DFS) final and overall ...
Morihito Okada, Shunichi Sugawara, Yasutaka Watanabe, Haruhiro Saito, Toyofumi F. Chen‐Yoshikawa, Yasushi Goto, Wataru Nishio, Shizuka Nakagawa, Morihiko Hayashi, Hirotsugu Kenmotsu   +9 more
wiley   +1 more source

Multiple Mononeuropathy Secondary to Parvovirus B19 Infection: A Case Series

European Journal of Neurology, Volume 33, Issue 3, March 2026.
Parvovirus B19 infection can cause multiple mononeuropathy in young and immunocompetent patients, predominantly affecting sensory nerves, with frequent involvement of the median, fibular, and ulnar nerves, as well as occasional cranial nerve impairment.
Julian Theuriet, Maud Michaud, Guillaume Fargeot, Céline Labeyrie, Anaïs Grosset, Maude Bucy, Ludivine Kouton, Florian Hubben, Véronique Manel, Florent Cluse, Adrien Bohic, Nicolas Rodriguez, Philippe Petiot, Geneviève Billaud, Vincent Fabry, Pascal Cintas, Thierry Maisonobe, Karine Viala, Rabab Debs, Dimitri Psimaras, Sarah Leonard‐Louis, Benjamin Terrier, Alina Dorobat, Céline Tard, Stéphane Darteyre, Alex Vicino, Marie Théaudin, Clovis Adam, Françoise Bouhour, Timothée Lenglet, Grégory Destras, Nathalie Streichenberger, Antoine Pegat   +32 more
wiley   +1 more source

Sex differences in cardiovascular disease and associated factors in people living with HIV: Evidence from All of Us program

HIV Medicine, Volume 27, Issue 3, Page 397-408, March 2026.
Abstract Background People living with HIV (PLWH) face a higher risk of cardiovascular disease (CVD), with significant sex differences in outcomes. However, it is unclear whether these differences are driven by distinct risk factor profiles or by a differential impact of shared risk factors.
Hao Zhang, Huiyi Xia, Fanghui Shi, Qingyang Li, Sharon Weissman, Xiaoming Li, Xueying Yang   +6 more
wiley   +1 more source

Sex Matters: Hormonal and Chromosomal Determinants of Autoimmunity and Anti‐Cancer Immunity Across the Lifespan

Immunological Reviews, Volume 338, Issue 1, March 2026.
ABSTRACT Sex plays a key role in shaping both anti‐cancer immunity and autoimmunity. Biological factors underlying sexual dimorphism have now been identified in multiple aspects of anti‐cancer immunity and autoimmunity. These factors include sex differences in hormone levels, chromosome complement, and expression of the long non‐coding RNA XIST.
Christian G. Bustillos, Esther M. Peluso, Sophia L. Cha, Melissa G. Lechner, Maureen A. Su   +4 more
wiley   +1 more source

Sex Differences in Response to Viral Vector Vaccines—Implications for Future Vaccine Design

Immunological Reviews, Volume 338, Issue 1, March 2026.
ABSTRACT Vaccination represents one of the most impactful public health achievements, preventing 3.5 to 5 million deaths annually according to estimates of the World Health Organization. Yet, recent outbreaks of emerging and reemerging infectious diseases highlight the need for rapid and strategic vaccine development using vaccine platforms ...
Ilka Grewe, Tamara Zoran, Marylyn Martina Addo   +2 more
wiley   +1 more source

The X Factor in Immunity: Sex Differences Shaped by the X Chromosome

Immunological Reviews, Volume 338, Issue 1, March 2026.
ABSTRACT There are sex differences with immune responses where females exhibit stronger immune responses compared to males. Both sex hormones and sex chromosome differences between males and females contribute to the observed sex differences with innate and adaptive immune cell composition and function.
Katherine B. Radovanovic, Megan Wynalda, Montserrat C. Anguera   +2 more
wiley   +1 more source